# Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma

> **NCT00169169** · PHASE3 · TERMINATED · sponsor: **Lymphoma Study Association** · enrollment: 430 (—)

## Conditions studied

- CD20-Positive Large B-Cell Lymphoma

## Interventions

- **DRUG:** ACVBP
- **DRUG:** ACE
- **DRUG:** rituximab
- **PROCEDURE:** Autologous stem cell transplant

## Key facts

- **NCT ID:** NCT00169169
- **Lead sponsor:** Lymphoma Study Association
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 1999-10
- **Primary completion:** —
- **Final completion:** 2005-08
- **Target enrollment:** 430 (—)
- **Last updated:** 2005-09-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00169169

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00169169, "Efficacy Study of Rituximab After ASCT in High-Risk Diffuse Large B-Cell Lymphoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00169169. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*